story of the week
Fulvestrant–Palbociclib vs Letrozole–Palbociclib as Initial Therapy for Endocrine-Sensitive, HR-Positive, ERBB2-Negative Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial
JAMA Oncol 2021 Oct 07;[EPub Ahead of Print], A Llombart-Cussac, JM Pérez-García, M Bellet, F Dalenc, M Gil-Gil, M Ruíz-Borrego, J Gavilá, M Sampayo-Cordero, E Aguirre, P Schmid, F Marmé, S Di Cosimo, J Gligorov, A Schneeweiss, J Albanell, P Zamora, D Wheatley, E Martínez-de Dueñas, K Amillano, A Malfettone, J CortésFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.